In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

An experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight. Randomized controlled trials (RCTs) assessed the efficacy and safety of ...

"Not all GLP-1s are the same." Retatrutide, the 'King Kong' drug to mimic bariatric surgery Eli Lilly isn't pivoting away from weekly weight loss injections entirely. It's also working on another ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Semaglutide produced nearly 14% weight loss after 68 weeks. Retatrutide generated weight loss of more than 22% after 48 weeks. Each of those drugs are taken once a week, by an injection.

Those who received GLP-1s experienced decreased absolute and relative weight loss vs. placebo across 26 randomized studies. Retatrutide conferred the greatest weight reduction among all GLP-1s.